Experimental chemotherapy for Chagas disease: 15 years of research contributions from in vivo and in vitro studies

Memorias do Instituto Oswaldo Cruz

Volumn 104, Issue SUPPL. 1, 2009, Pages 301-310

  Soeiro, Maria de Nazaré C ^a   Dantas, Andréia P ^a   Daliry, Anissa ^a   da silva, Cristiane F ^a   Batista, Denise G J ^a   de souza, Elen M ^a   Oliveira, Gabriel M ^a   Salomão, Kelly ^a   Batista, Marcos Meuser ^a   Pacheco, Michelle G O ^a   da silva, Patrícia Bernardino ^a   Santa Rita, Ricardo M ^b   Menna Barreto, Rubem F S ^a   Boykin, David W ^c   de Castro, Solange Lisboa ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^c GEORGIA STATE UNIVERSITY   (United States)

Author keywords

Aromatic diamidines; Chagas disease; Dimethyl propenamines; Experimental chemotherapy; N,N; Naphthoquinones; Propolis; Trypanosoma cruzi

Indexed keywords

TRYPANOSOMA CRUZI;

EID: 68949210749     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/S0074-02762009000900040     Document Type: Article

References (101)

1. Anonymous 2006. Chagas' disease - an epidemic that can no longer be ignored. Lancet 368: 619.
2. Apt W, Arribada A, Zulantay I, Solari A, Sánchez G, Mundaca K, Coronado X, Rodríguez J, Gil LC, Osuna A 2005. Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: the results of clinical and parasitological examinations 11 years post treatment. Ann Trop Med Parasitol 99: 733-741.
3. Arenas P 1987. Medicine and magic among the Maka Indians of the Paraguayan Chaco. J Ethnopharmacol 21: 279-295.
4. Bankova VS, De Castro SL, Marcucci MC 2000. Propolis: recent advances in research on chemistry and plant origin. Apidologie 31: 3-15.
5. Barrett MP, Burchmore RJ, Stich A, Lazzari JO, Frasch AC, Cazzulo JJ, Krishna S 2003. The trypanosomiases. Lancet 362: 1469-1480.
6. Barrett PA, Beveridge E, Bull D, Caldwell IC, Islip PJ, Neal RA, Woods NC 1982. The efficacy of a novel compound, (E)-1-(4́-bromo-4-biphenylyl)-1-(4-chlorophenyl)-3-dimethylaminoprop-1-ene against Trypanosoma cruzi in mice. Experientia 38: 338-339.
7. Bastien JW 1983. Pharmacopeia of Qollahuaya Andeans. J Ethno-pharmacol 8: 97-111.
8. Bilate AM, Cunha-Neto E 2008. Chagas disease cardiomyopathy: current concepts of an old disease. Rev Inst Med Trop Sao Paulo 50: 67-74.
9. Blandon R, Johnson CM, Sousa O, Leandro I, Guevara JF 1993. The clinical experience in Panama with metronidazole in treating Chagas' disease in the acute and chronic phases. Rev Med Panama 18: 94-100.
10. Blum J, Desjeux P, Schwartz E, Beck B, Hatz C 2004. Treatment of cutaneous leishmaniasis among travelers. J Antimicrob Chemother 53: 158-166.
11. Bray PG, Barrett MP, Ward SA, de Koning HP 2003. Pentamidine uptake and resistance in pathogenic protozoa: past, present and future. Trends Parasitol 19: 232-239.
12. Brener Z, Cançado JR, Galvão LM, Da Luz ZM, Filardi LS, Pereira ME, Santos LM, Cançado CB 1993. An experimental and clinical assay with ketoconazole in the treatment of Chagas disease. Mem Inst Oswaldo Cruz 88: 149-153.
13. Carter NS, Berger BJ, Fairlamb AH 1995. Uptake of diamidine drugs by the P2 nucleoside transporter in melarsen-sensitive and -resistant Trypanosoma brucei brucei. J Biol Chem 270: 28153-28157.
14. Chabala JC, WQaits VB, Ikeler T, Patchett AA, Payne L, Peterson LH, Reamer RA, Hoogsteen K, Wyvratt M, Hanson WL, Fisher MH 1991. 1-(substituted)benzyl-5-aminiimidazole-4-carboxam-ides are potent orally active inhibitors of Trypanosoma cruzi in mice. Experientia 47: 51-53.
15. Chagas C 1909. Nova tripanosomíase humana - Estudos sobre a mor-fologia e o ciclo evolutivo de Schizotrypanum cruzi gen. nov. sp. nov., agente etiológico de nova entidade mórbida do homem. Mem Inst Oswaldo Cruz 1: 159-218.
16. Chaves JP, Pinto MCFR, Pinto AV 1990. Heterocyclics from quino-nes. I - Reaction of lapachol with primary alkyl amines. J Braz Chem Soc 1: 21-27.
17. Coura JR 2007. Chagas disease: what is known and what is needed - A background article. Mem Inst Oswaldo Cruz 102: 113-122.
18. Coura JR, De Castro SL 2002. A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz 97: 3-24.
19. Cunha IBS, Salomão K, Shimizu M, Bankova VS, Custódio AR, De Castro SL, Marcucci MC 2004. Anti-trypanosomal activity of Brazilian propolis from Apis mellifera. Chem Pharm Bull 52: 602-604.
20. Dantas AP, Barbosa HS, De Castro SL 2003. Biological and ultra-structural effects of the anti-microtubule agent taxol against Trypanosoma cruzi. J Submicr Cytol Pathol 35: 287-294.
21. Dantas AP, Olivieri BP, Gomes FHM, De Castro SL 2005. Treatment of Trypanosoma cruzi-infected mice with propolis promotes changes in the immune response. J Ethnopharmacol 103: 187-193.
22. Dantas AP, Salomão K, Barbosa HS, De Castro SL 2006. The effect of Bulgarian propolis against Trypanosoma cruzi. Mem Inst Os-waldo Cruz 101: 207-211.
23. De Castro SL 2001. Propolis: biological and pharmacological activities. Therapeutic uses of this bee-product. Ann Rev Biol Sci 3: 49-83.
24. De Castro SL, Higashi KO 1995. Effect of different formulations of propolis on mice infected with Trypanosoma cruzi. J Ethnophar-macol 46: 55-59.
25. De Castro SL, Pinto MCFR, Pinto AV 1994. Screening of natural and synthetic drugs against Trypanosoma cruzi. 1 - Establishing a structure/activity relationship. Microbios 78: 83-90.
26. De Conti R, Gimenez SMN, Haun M, Pilli RA, De Castro SL, Durán N 1996a. Synthesis and biological activities of N,N-dimethyl-2-propen-1-amine derivatives. Eur J Med Chem 31: 915-918.
27. De Conti R, Oliveira DA, Fernandes AMAP, Melo PS, Rodriguez JA, Haun M, De Castro SL, Souza-Brito ARM, Durán N 1998. Appli-cation of a multi-endpoint cytotoxicity assay to the trypanocidal compounds 2-propen-1-amine derivatives and determination of their acute toxicity. In Vitro Mol Toxicol 11: 153-160.
28. De Conti R, Santa-Rita RM, de Souza EM, Melo PS, Haun M, De Castro SL, Durán N 1996b. In vitro trypanocidal activities of a novel series of N,N-dimethyl-2-propen-1-amine derivative. Mi-crobios 85: 83-87.
29. De Souza EM, Lansiaux A, Bailly C, Wilson, WD Hu, Q, Boykin DW, Batista MM, Araújo-Jorge TC, Soeiro MNC 2004. Phenyl substitution of furamidine markedly potentiates its antiparasitic activity against Trypanosoma cruzi and Leishmania amazonensis. Biochem Pharmacol 68: 593-600.
30. De Souza EM, Melo G, Boykin DW, Wilson WD, Hu Q, Soeiro MNC 2006a. Tripanocidal activity of the phenyl-substituted analogue of furamidine DB569 against Trypanosoma cruzi infection in vivo. J Antimicrob Chemoth 58: 610-614.
31. De Souza EM, Menna-Barreto R, Araújo-Jorge TC, Kumar A, Hu Q, Boykin DW, Soeiro MNC 2006b. Antiparasitic activity of aromatic diamidines is related to apoptosis-like death in Trypano-soma cruzi. Parasitology 133: 75-79.
32. De Souza EM, Oliveira GM, Soeiro MNC 2007. Electrocardiographic findings in acutely and chronically Trypansoma cruzi-infected mice treated by a phenyl-substituted analogue of furamidine DB569. Drug Targets Insights 2: 61-69.
33. Dias JC 2007. Globalization, inequity and Chagas disease. Cad Saude Publica 23 (Suppl.): S13-22.
34. Dykstra CC, McClernon DR, Elwell LP, Tidwell RR 1994. Selective inhibition of topoisomerases from Pneumocystis carinii compared with that of topoisomerases from mammalian cells. Anti-microb Agents Chemother 38: 1890-1898.
35. Goulart MOF, Falkowski P, Ossowski T, Liwo A 2003. Electrochemi-cal study of oxygen interaction with lapachol and its radical an-ions. Bioelectrochemistry 59: 85-87.
36. Hegazi AG, Abd-El-Hady FK, Abd-Allah FA 2000. Chemical compo-sition and antimicrobial activity of European propolis. Z Natur-forsch 55: 70-75.
37. Higashi KO, De Castro SL 1994. Propolis extracts are effective against Trypanosoma cruzi and have an impact on its interaction with host cells. J Ethnopharmacol 43: 149-155.
38. Higuchi ML, Benvenuti LA, Martins-Reis M, Metzger M 2003. Pathophysiology of the heart in Chagas' disease: current status and new developments. Cardiovasc Res 60: 96-107.
39. Lopes CC, Lopes RSC, Pinto AV, Costa PRR 1984. Efficient synthe-sis of cytotoxic quinones: 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione, J Heterocyclic Chem 21: 621-622.
40. Lüllmann H, Lüllmann-Rauch R, Wassermann O 1978. Lipidosis induced by amphiphilic cationic drugs. Biochem Pharmacol 27: 1103-1108.
41. Machado GM, Leon LL, De Castro SL 2007. Activity of Brazilian and Bulgarian propolis against different species of Leishmania. Mem Inst Oswaldo Cruz 102: 73-77.
42. Marcucci MC 2000. Process to typing natural products. Requested patent. Brazilian National Institute for Intellectual Property -INPI, n° PI 0105471-6, 22 December.
43. Marcucci MC, Ferreres F, García-Viguera C, Bankova VS, De Castro SL, Dantas AP, Valente PHM, Paulino N 2001. Phenolic com-pounds from Brazilian propolis with pharmacological activities. J Ethnopharmacol 74: 105-112.
44. Marino AP, Silva AA, Santos PV, Pinto LM, Gazinelli RT, Teixeira MM, Lannes-Vieira J 2005. CC-chemokine receptors: a potential therapeutic target for Trypanosoma cruzi-elicited myocarditis. Mem Inst Oswaldo Cruz 100 (Suppl. I): 93-96.
45. Mathis AM, Bridges AS, Ismail MA, Kumar A, Francesconi I, An-bazhagan M, Hu Q, Tanious FA, Wenzler T, Saulter J, Wilson WD, Brun R, Boykin DW, Tidwell RR, Hall JE 2007. Diphenyl furans and aza analogs: effects of structural modification on in vitro activity, DNA binding, and accumulation and distribution in trypanosomes. Antimicrob Agents Chemother 51: 2801-2810.
46. Mathis AM, Holman JL, Sturk LM, Ismail MA, Boykin DW, Tidwell RR, Hall JE 2006. Accumulation and intracellular distribution of antitrypanosomal diamidine compounds DB75 and DB820 in Afri-can trypanosomes. Antimicrob Agents Chemother 50: 2185-2191.
47. McCabe RE, Araújo FG, Remington JS 1983. Ketoconazole protects against infection with Trypanosoma cruzi in a murine model. Am J Trop Med Hyg 32: 960-962.
48. Menna-Barreto RFS, Corrêa JR, Cascabulho CM, Fernandes MC, Pinto AV, Soares MJ, De Castro SL 2009a. Naphthoimidazoles promote different death phenotypes in Trypanosoma cruzi. Pa-rasitology 136: 499-510.
49. Menna-Barreto RFS, Corrêa JR, Pinto AV, Soares MJ, De Castro SL 2007. Mitochondrial disruption and DNA fragmentation in Try-panosoma cruzi induced by naphthoimidazoles synthesized from β-lapachone. Parasitol Res 101: 895-905.
50. Menna-Barreto RFS, Gonçalves RLS, Costa M, Silva RSF, Pinto AV, Oliveira MF, De Castro SL 2009b The activity against Try-panosoma cruzi of novel synthetic naphtoquinones is mediated by mitochondrial dysfunction and oxidative stress. Free Rad Biol Med, in press.
51. Menna-Barreto RFS, Henriques-Pons A, Pinto AV, Morgado-Diaz JA, Soares MJ, De Castro SL 2005. Effect of a β-lapachone-derived naphthoimidazole on Trypanosoma cruzi: identification of target organelles. J Antimicrob Chemother 56: 1035-1041.
52. Menna-Barreto RFS, Salomão K, Dantas AP, Santa-Rita RM, Soares MJ, Barbosa HS, De Castro SL 2009c. Different cell death path-ways induced by drugs in Trypanosoma cruzi: an ultrastructural study. Micron 40: 157-168.
53. Monks TJ, Hanslik RP, Cohen GM, Ross D, Graham DG 1992. Qui-none chemistry and toxicity. Toxicol Appl Pharmacol 112: 2-16.
54. Moura KCG, Emery FS, Neves-Pinto C, Pinto MCFR, Dantas AP, Sa-lomão K, De Castro SL, Pinto AV 2001. Synthesis and trypanocidal activity of naphthoquinones isolated from Tabebuia and heterocyclic derivatives: a review from an interdisciplinary study. J Braz Chem Soc 12: 325-338.
55. Moura KCG, Salomão K, Menna-Barreto RFS, Emery FS, Pinto MCFR, Pinto AV, De Castro SL 2004. Studies on the trypanocidal activity of semi-synthetic pyran[b-4,3]naphtho[1,2-d]imidazoles from β-lapachone. Eur J Med Chem 39: 639-645.
56. Neves-Pinto C, Dantas AP, De Moura KCG, Emery FS, Polequevitch PF, Pinto MCFR, De Castro SL, Pinto AV 2000. Chemical re-activity studies with naphthoquinones from Tabebuia with anti-trypanosomal efficacy. Arzneim-Forsch 50: 1120-1128.
57. Neves-Pinto C, Malta VRS, Pinto MCFR, Santo RHA, De Cas-tro SL, Pinto AV 2002. Trypanocidal phenazine derived from β-lapachone. J Med Chem 45: 2112-2115.
58. Nothemberg MS, Takeda GKF, Najjar R 1991. Adducts of nitroimi-dazole derivatives with Rhodium(II) carboxylates: synthesis, characterization and evaluation of antichagasic activities. J Inorg Biochem 42: 217-229.
59. Nwaka S, Hudson A 2006. Innovative lead discovery strategies for tropical diseases. Nat Rev Drug Discov 5: 941-955.
60. O'Brien PJ 1991. Molecular mechanism of quinone cytotoxicity. Chem-Biol Interact 80: 1-41.
61. Oliveira DA, Pereira DG, Fernandes AMAP, De Castro SL, Souza Brito ARM, De Souza AO, Durán N 2005. Trypanocidal activity of 2-propen-1-amine derivatives on trypomastigotes culture and in animal model. Parasitol Res 95: 161-166.
62. Olliaro P, Guerin P, Gerstl S, Haaskjold A, Rottingen J, Sundar S 2005. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect Dis 5: 763-774.
63. Pacheco MGO, Silva CF, De Souza EM, Batista MM, Silva PB, Ku-mar A, Stephens CE, Boykin DW, Soeiro MNC 2009. Trypanosoma cruzi: activity of heterocyclic cationic molecules in vitro. Exp Parasitol, in press.
64. Park YK, Alencar SM, Aguiar CL 2002. Botanical origin and che-mical composition of Brazilian propolis. J Agric Food Chem 50: 2502-2506.
65. Paulino N, Dantas AP, Bankova VS, Longhi DT, Scremin A, De Castro SL, Calixto JB 2003. Bulgarian propolis induces analgesic and anti-inflammatory effects in mice and inhibits in vitro contraction of airway smooth muscle. J Pharmacol Sci 93: 307-313.
66. Pereira DG, De Castro SL, Durán N 1998. Activity of N,N-dimethyl-2-propen-1-amine derivatives in mice experimentally infected with Trypanosoma cruzi. Acta Trop 69: 205-211.
67. Pinto AV, Ferreira VF, Pinto MCFR, Mayer LU 1985. Reaction of 2-amino-1,4-naphthoquinone derivatives with dimethyl acety-lenedicarboxylate. Synthetic Comm 15: 1181-1189.
68. Pinto AV, Menna-Barreto RFS, De Castro SL 2007. Naphthoquinones isolated from Tabebuia: a review about the synthesis of hetero-cyclic derivatives, screeening against Trypanosoma cruzi and correlation structure-trypanocidal activity. Phytomedicines. In: Recent progress in medicinal plants, JN Govil (ed.), vol. 16, Studium Press, Houston, p. 112-127.
69. Pinto AV, Neves Pinto C, Pinto MCFR, Emery FS, De Moura KCG, Carvalho CEM, Brinn IM 1997a. Fluorescent symmetric phenazines from naphthoquinones. Heterocycles 45: 2431-2436.
70. Pinto AV, Neves Pinto C, Pinto MCFR, Santa Rita RM, Pezzella C, De Castro SL 1997b. Trypanocidal activity of synthetic heterocyclic derivatives from active quinones from Tabebuia sp. Arzneim-Forsch 47: 74-79.
71. Pinto AV, Pinto MCFR, Aguiar MA, Capella RS 1982. Transforma-ções do lapachol em nafto-[1,2-b]-furanaquinonas naturais. An Acad Bras Cienc 54: 115-118.
72. Prytzyk E, Dantas AP, Salomão K, De Castro SL, Pereira AS, Bankova VS, Aquino Neto FR 2003. Flavonoids and trypanocidal of Bulgarian propolis. J Ethnopharmacol 88: 189-193.
73. Rocha MO, Teixeira MM, Ribeiro AL 2007. An update on the management of Chagas cardiomyopathy. Expert Rev Anti Infect Ther 5: 727-743.
74. Rosypal AC, Hall JE, Bakunova S, Patrick DA, Bakunov S, Stephens CE, Kumar A, Boykin DW, Tidwell RR 2007. In vitro activity of dicationic compounds against a North American foxhound iso-late of Leishmania infantum. Vet Parasitol 145: 207-216.
75. Rosypal AC, Werbovetz KA, Salem M, Stephens CE, Kumar A, Boykin DW, Hall JE, Tidwell RR 2008. Inhibition by dications of in vitro growth of Leishmania major and Leishmania tropica: causative agents of old world cutaneous leishmaniasis. J Parasi-tol 94: 743-749.
76. Salomão K, Dantas AP, Borba CM, Campos LC, Machado DG, Aquino Neto FR, De Castro SL 2004. Chemical composition and microbicidal activity of extracts from Brazilian and Bulgarian propolis. Lett Appl Microbiol 38: 87-92.
77. Salomão K, Pereira PRSCS, Campos LC, Borba CM, Cabello PH, Marcucci MC, De Castro SL 2008. Brazilian propolis: correlation between chemical composition and microbicidal activity. Evid-Based Compl Altern Med 5: 317-324.
78. Salomão K, Souza EM, Henriques-Pons A, Barbosa HS, de Castro SL 2009. Brazilian green propolis: effects in vitro and in vivo on Trypanosoma cruzi. Evid-Based Compl Altern Med, in press.
79. Schmunis GA 2007. Epidemiology of Chagas disease in non-endemic countries: the role of international migration. Mem Inst Oswaldo Cruz 102 (Suppl. I): 75-85.
80. Sepulveda-Boza S, Cassels BK 1996. Plant metabolites active against Trypanosoma cruzi. Planta Med 62: 98-105.
81. Shapiro TA, Englund PT 1990. Selective cleavage of kinetoplast DNA minicircles promoted by antitrypanosomal drugs. Proc Natl Acad Sci 87: 950-954.
82. Silva CF, Batista MM, Batista DG, de Souza EM, Silva PB, Oliveira GM, Batista MM, Shareef AR, Boykin DW, Soeiro MNC 2008. In vitro and in vivo studies of the trypanocidal activity of a dia-rylthiophene diamidine against Trypanosoma cruzi. Antimicrob Agents Chemother 52: 3307-3314.
83. Silva CF, Batista MM, De Souza EM, Meirelles MNL, Stephens CE, Som P, Boykin DW, Soeiro MNC 2007a. Cellular effects of reversed amidines on Trypanosoma cruzi. Antimicrob Agents Chemother 51: 3803-3809.
84. Silva CF, Batista MM, Mota RA, De Souza EM, Stephens CE, Som P, Boykin DW, Soeiro MNC 2007b. Activity of "reversed" diamidines against Trypanosoma cruzi in vitro. Biochemical Pharma-col 73: 1939-1946.
85. Silva Jr EM, Menna-Barreto RFS, Pinto MCFR, Silva RSF, Teixeira DV, Souza MCBV, de Simone CA, De Castro SL, Ferreira VF, Pinto AV 2008a. Naphthoquinoidal [1,2,3]-triazole, a new struc-tural moiety active against Trypanosoma cruzi. Eur J Med Chem 43: 1774-1780.
86. Silva Jr EM, Souza MCBV, Fernandes MC, Menna-Barreto RFS, Pin-to MCFR, Lopes FA, Simone CA, Andrade CK, Pinto AV, Ferreira VF, De Castro SL 2008b. Synthesis and anti-Trypanosoma cruzi activity of derivatives from nor-lapachones and lapachones. Bioorganic Med Lett 16: 5030-5038.
87. Silva RSF, Costa EM, Trindade ULT, Teixeira DV, Pinto MCFR, Santos GL, Malta VRS, De Simone CA, Pinto AV, De Castro SL 2006. Synthesis of naphthofuranquinones with activity against Trypanosoma cruzi. Eur J Med Chem 41: 526-530.
88. Singh G, Dey CS 2007. Induction of apoptosis-like cell death by pentamidine and doxorubicin through differential inhibition of topoisomerase II in arsenite-resistant Leishmania donovani. Acta Trop 103: 172-185.
89. Soeiro MNC, De Castro SL 2009. Trypanosoma cruzi targets for new chemotherapeutic approaches. Expert Opin Ther Targets 13: 105-121.
90. Soeiro MNC, de Castro SL, Souza EM, Batista DGJ, Silva CF, Boykin DW 2008. Diamidines activity upon trypanosomes: the state of the art. Curr Mol Pharmacol 1: 151-161.
91. Soeiro MNC, De Souza EM, Stephens CE, Boykin DW 2005. Aromatic diamidines as antiparasitic agents. Expert Opin Investig. Drugs 14: 957-972.
92. Solari A, Saavedra H, Sepulveda C, Oddó D, Acuña G, Labarca J, Muñoz S, Cuny G, Brengues C, Veas F, Bryan RT 1993. Successful treatment of Trypanosoma cruzi encephalitis in a patient with hemophilia and AIDS. Clin Inf Dis 16: 255-259.
93. Souto-Padron T, Cunha-Silva NL, De Souza W 1993. Acetylated α-tubulin in Trypanosoma cruzi: immunocytochemical localiza-tion. Mem Inst Oswaldo Cruz 88: 517-528.
94. Souza AO, Hemerly FP, Busollo AC, Melo PS, Machado GMC, Miran-da CC, Santa-Rita RM, Haun M, Leon LL, Sato DN, De Castro SL, Durán N 2002. 3-[4'-bromo-(1,1'-biphenyl)-4-yl]-N,N-dim-ethyl-3-(2-thienyl)-2-propen-1-amine: synthesis, cytotoxicity, trypanocidal, leishmanicidal and antimycobacterial activities. J Antimicrobial Chemother 50: 629-637.
95. Souza AO, Hemerly FP, Gomes-Cardoso L, Santa-Rita R, Leon LL, De Castro SL, Duran N 2004. 2-Propen-1-amine derivatives and their synthetic intermediates: activity against pathogenic try-panosomatids. J Chemother 16: 530-533.
96. Stephens CE, Brun R, Salem MM, Werbovetz KA, Tanious F, Wilson WD, Boykin DW 2003. The activity of diguanidino and "reversed" diamidino 2,5-diarylfurans versus Trypanosoma cruzi and Leish-mania donovani. Bioorg Med Chem Lett 13: 2065-2069.
97. Trusheva B, Popova M, Bankova VS, Simova S, Marcucci MC, Mio-rin PL, da Rocha Pasin F, Tsvetkova I 2006. Bioactive constituents of Brazilian red propolis. Evid-Based Compl Altern Med 3: 249-254.
98. Vaidian AK, Weiss LM, Tanowitz HB 2004. Chagas' disease and AIDS. Kinetoplastid Biol Dis 3: 2.
99. Werbovetz K 2006. Diamidines as antitrypanosomal, antileishmanial and antimalarial agents. Curr Opin Investig Drugs 7: 147-157.
100. Wilson WD, Tanious FA, Mathis A, Tevis D, Hall JE, Boykin DW 2008. Antiparasitic compounds that target DNA. Biochimie 90: 999-1014.
101. Winkelmann E, Raether W, Sinharay A 1978. Chemotherapeutically active nitro compounds. 4,5-Nitroimidazoles (Part II). Arzneim-Forsch 28: 351-366.